Gene therapy is one of the most attractive fields in tumor therapy. In past decades, significant progress has been achieved. Various approaches, such as viral and non鄄 viral vectors and physical methods, have been developed to make gene delivery safer and more efficient. Several therapeutic strategies have evolved, including gene鄄 based (tumor suppressor genes, suicide genes, antiangiogenic genes, cytokine and oxidative stress鄄 based genes) and RNA鄄 based (antisense oligonucleotides and RNA interference) approaches. In addition, immune response鄄 based strategies (dendritic cell-and T cell-based therapy) are also under investigation in tumor gene therapy. This review highlights the progress and recent developments in gene delivery systems, therapeutic strategies, and possible clinical directions for gene therapy.
Gene therapy involves the transfer of nucleic acids to somatic cells for the treatment of genetic disorders in humans. In this therapy, diseasecausing genes are removed or replaced with normal or functional genes to fulfill the enzyme or protein requirement of the body [1] . The disease is expected to be eliminated after gene therapy.
The idea of gene therapy was introduced by Joshua Lederberg in 1963; however, research on human genetics did not accelerate until the 1980s. Subsequently, the first clinical study on gene transfer was conducted by Anderson . [2] in 1990. In that study, a 4yearold girl with adenosine deaminase (ADA) deficiency was treated by transfecting the ADA gene into her white blood cells, resulting in considerable improvements in her immune system [2] . In the same year, gene therapy was also tested on patients suffering from melanoma, and the results showed that retroviral gene transfer was safe and practical [3] . Since 1989, more than 900 clinical trials on gene therapy have been approved worldwide. Among these trials, 70% are in the area of cancer gene therapy [3, 4] . To date, substantive progress has been made in gene therapy, and this progress has benefited from advancements in the therapeutic strategies discussed next.
Gene Delivery Systems
Although considerable strides have been made in developing genebased therapeutic strategies, establishing efficient and safe gene delivery systems remains the main challenge in tumor gene therapy. The gene therapy vectors used in gene delivery systems can be categorized into two groups: viral and nonviral systems.
Viral systems
Viral vectors, which can transfer genetic materials into host cells, are biological systems derived from naturally evolved viruses. Viruses used in gene therapy have been modified to increase safety, enhance specific uptake, and improve efficiency. The viral vectors include retrovirus, adenovirus, Herpes simplex virus (HSV), adenoassociated virus (AAV), and poxvirus (vaccina virus) [5] . The most commonly used DNA viral vectors are based on adenoviruses and AAVs. The understanding of viral vectors has increased greatly and their design and production have been improved. Several clinical trials have been performed for various viral vectors [6, 7] . However, there are some drawbacks in terms of the safety and toxicity of these vectors and the size of the transfected genetic material. Therefore, great caution should be exercised when using viral vectors for the treatment of human diseases, and this topic should be investigated further.
Non鄄 viral systems
The limitations associated with viral vectors have encouraged researchers to focus on nonviral systems. Many methods have been developed for the nonvirusmediated delivery of genetic materials, including nonviral vectors and physical approaches.
Nonviral vectors are safe, can be constructed and modified by simple methods, and exhibit high gene encapsulation ability [5] . Nonviral vectors include cationic polymers like polyethylenimine (PEI) and polyLlysine (PLL), cationic peptides, and cationic liposomes. Among these vectors, liposome is widely used in clinical trials for tumor therapy. In HLAB7negative melanoma patients, antitumor immunity is induced by injecting cationic liposomes containing HLAB7 and 茁 2 microglobulinencoding genes [6, 8] . Further, patients with glioblastoma have been treated with cationic liposomes containing the 茁 interferon encoding gene [9] . Hence, liposomes are considered safe for use in humans.
Shell nanoparticles, the newly described cationic core, offer more advantages than liposomes, namely, high gene transfection efficiency and concurrent delivery of drugs and genes to the same cells [10] . Another advantage of nanoparticlebased therapeutic strategies is that they simultaneously have enhanced efficacy and reduced adverse effects. This advantage can be attributed to properties such as their passive and active targeting [11] . Passive targeting allows effective localization of targets in tumor cells based on 野enhanced permeability and retention (EPR)冶 [7] . Coating nanoparticles with targeting molecules, such as antibodies, peptides, nucleic acid aptamers, carbohydrates, and small molecules, can enhance the cellular uptake of nanoparticles. For example, using a Wistar rat model which had implanted with folate receptorexpressing C6 glioma cells, significant growth inhibition of C6 glioma xenografts was observed after treatment with nanoparticle/targeting molecule combinations, FAPEGPEI/pCD/5FC and FAPEGPEI/pTRAIL [12] . Unlike other types of therapeutic agents, nanoparticles allow for custom design and propertytuning. Further, as more clinical data [13, 14] becomes available and the optimal therapeutic properties of nanoparticles becomes clear, the nanoparticlebased approach will continue to improve.
Naked DNAbased gene therapy is an attractive approach because it eliminates or reduces the disadvantages of viral vectors [15] . However, naked DNA is prone to tissue clearance and cannot be delivered effectively. Thus, physical approaches have been developed to facilitate plasmid DNA delivery . Electroporation Electroporation (EP) is an efficient and simple method for the DNA delivery. This technique is based on the principle that applying electric pulses across the cell membrane creates a transmembrane potential difference, allowing transient membrane permeation and facilitating the insertion of DNA through the destabilized membrane [16] . EP is a safe and possible treatment approach and has been used to transfer genes into the cells of skeletal muscles, tumors, brain, liver, skin, and other tissues. Among these experiments, 38% are related to cancer treatment [16] . Moreover, genes related to immune response are mostly used in EPmediated tumor treatment. To date, interleukin12 (IL12) and interferon琢 (IFN琢 ) are the most successful cancer therapeutic genes delivered by EP in experimental models. Intratumor EP of IL12 cDNAencoding plasmid into melanomas has now reached clinical trials. In 2008, Daud .
[17] confirmed that IL12 delivery by EP was effective. Subsequently, other clinical trials for cancers expressing human epidermal growth factor receptor2 (HER2) and carcinoembryonic antigen (CEA) [18] have commenced. The true potential of this delivery approach will not be known until the results of the aforementioned and other clinical trials have been reported. Ultrasound Although EP is more efficient, microbubble enhanced ultrasound causes less damage and is less invasive [19] . As a therapeutic application, ultrasound can generally be used to deliver ultrasound energy directly to an object and to enhance the delivery of therapeutic drugs and genes [20] . In eukaryotic cells, the transcription of heat shock protein (HSP) is markedly enhanced after exposure to temperature conditions above those required for maximum growth [20, 21] . The ability of HSP promoter to respond to highintensity focused ultrasound (HIFU) has been demonstrated in various studies [20, 22] . The results from those studies indicated that gene expression was increased at high temperatures after exposure to HIF [22, 23] . This approach enhances the spatial targeting and the efficiency of gene delivery.
In addition, ultrasound can enhance gene delivery by altering vascular permeability in a method called sonoporation. Sonoporation has been applied in many tissues, including tumors [19] , and has been used to deliver oligonucleotides and small interfering RNA (siRNA)to tumors. In the treatment of prostatic tumors, microbubble and ultrasound have been applied to target siRNA to the androgen receptor [ 24 ] . Hecht . [ 25 ] reported that they have successfully administered an intratumoral endoscopic ultrasound injection of ONYX015 and an intravenous injection of gemcitabine to patients with unresectable pancreatic carcinoma.
To develop more applications and improve the existing ones, an indepth understanding of the ultrasound mechanisms discussed herein is required.
Other approaches There are several approaches for nonviral gene therapy in addition to those mentioned before. The hydrodynamicbased method affords efficient gene transfer and expression by rapid injection of a large volume of DNA solution through the tail vein of an animal. However, this technique may be harmful for the experimental animal [26] . Gene gun immunization through the skin is a reliable and reproducible method of DNA vaccine delivery. This method can induce immune response against both infectious diseasecausing agents and cancer in animal models. DNA delivery using this approach requires 2502500 times less DNA than the standard method of intramuscular delivery [27] . Further, the gene gun immunization is a highly efficient method of achieving antigen presentation. Minicircle DNA (mcDNA) is a novel form of supercoiled DNA containing only the therapeutic gene expression cassette and not the bacterial backbone genome [28] . It is generated by sitespecific recombination in [ 29, 30 ] . mcDNA is superior to conventional plasmid because the former exhibits improved gene expression efficiency and prolongs the time span in transfected cells [28, 29, 31] . Darquet . [32] reported that the injection of mcDNA leads to 13 to 50fold increase in reporter gene expression in skeletal muscle and human carcinoma grafts in nude mice compared to the injection of an equal amount of parental plasmid. Further, Chen . [29] reported that the expression of a transgene in mcDNAtransfected mouse liver was 45 to 560 folds greater than in standard DNAtransfected mouse liver. Wu .
[33] achieved a remarkable antinasopharyngeal carcinoma effect by performing mcDNAmediated IFN酌 gene transfer in nude mouse. Further, mcDNA is a safe vehicle to achieve the deletion of antibiotic resistance genes.
Gene鄄 Based Therapeutic Strategies
Due to the complex nature of cancers, a variety of genebased therapeutic strategies have been used in tumor gene therapy.
Tumor suppressor gene therapy
A mutation or deficiency in tumor suppressor genes (TSGs) is critical for the multistep development and progression of human malignancies. TSGs include , , , , , , and as well as the newly discovered . Among these genes, the prevalence of is high in human tumors, and it is one of the most studied TSGs. In 2003, drug license, production approval, and good manufacturing practice certificate were successfully obtained from the China State Food & Drug Administration [34] for recombinant human Adp53, and it became the world爷s first commercialized gene therapeutic product to receive approval. In addition to the treatment of tumors with null or mutant genotype, p53 gene therapy has been proved to be effective against tumors with wildtype p53, especially when used in combination with chemotherapy or radiotherapy [35, 36] .
Suicide gene therapy
Suicide gene therapy is also termed as gene directed enzyme prodrug therapy (GDEPT) [37] , and this approach has attracted increasing attention. GDEPT has potential advantages over conventional therapy in that it involves specific activation of target cells and has an expanded killing effect called the 野bystander effect.冶 The GDEPT approach encompasses several therapeutic systems , such as VZVtk/AraM , NTR/CB1954 [ 38 ] , CPG2/ CMDA [39] , PNP/6MePdR [40] , HSVTK/GCV, and CD/5FCB [7, 10] . HSVTK/GCV and CD/5FCB are the best characterized systems [37] , and clinical trials using HSVTK are currently in the phase III stage. Despite its advantages, suicide gene therapy exhibits limited efficiency due to low targeting potential, suicide gene expression, catalytic activity of the enzyme product, and killing effects. In view of these shortcomings, several efforts are directed toward modifying suicide genes, screening for new prodrugs, combining GDEPT with traditional therapies, and improving tumor targeting [41, 42] . For example, Dilber .
[43] designed a fusion protein comprising HSVTK and the HSV1 tegument protein VP22. This fusion protein is more efficient than HSVTK alone [43] . Further studies will help determine if this method can be applied for clinical purposes.
Antiangiogenic gene therapy
Angiogenesis is an important process that supports the growth of solid tumors; therefore, inhibiting angiogenesis might accordingly arrest tumor growth. Several negative regulators of angiogenesis, such as angiostatin, endostatin, vasostatin, modulators of vascular endothelial growth factor activity (sFLT1), and cytokines/chemokines with marked antiendothelial activity (IL12, IFNα , CXCL10, and others) [44] , have been used in tumor therapy. We have constructed a replicationdefective adenovirus carrying human endostatin gene (E10A) and have started evaluating its effects on solid tumors in phase II clinical trials [45] . The results of this study showed that our construct had promising therapeutic effects.
Cytokine鄄 based gene therapy
Cytokinebased therapy is an attractive approach to modulate and enhance the immune response to tumors. The cytokines investigated include IL2, IL1, IL12, IFN琢 , GMCSF, IL4, and IFN酌 . Among them, GMCSF and IL12 are the most widely studied [46] . A phase I study designed to determine the use of IL12 plasmid/lipopolymer complexes in treating recurrent ovarian cancer revealed that this approach is generally safe and well tolerated [47] . Similarly, a phase I clinical trial was conducted to determine the safety of adenovirus vectormediated delivery of the IL12 gene for recurrent or persistent prostate cancer [48] . Recent research suggests that combination immunotherapy may possess remarkable potential for clinical applications, although more tests are warranted to confirm the efficacy of this treatment.
Oxidative stress鄄 based gene therapy
Oxidative stress, namely overproduction of reactive oxygen species (ROS), has several protumorigenic effects, such as increasing DNA mutation rate and inducing DNA damage, genome instability, and cell proliferation. Conversely, it can also be developed to kill tumors by delivering excessive oxidative stress into tumor cells or by disrupting the antioxidative defense systems of tumor cells [4951] . One approach to achieve this killing effect is to deliver ROSgenerating enzymes, such as glucose oxidase or xanthine oxidase, to tumor tissues directly. Stegman . [52] transferred the gene encoding 琢 amino acid oxidase (DAAO) into glioma cells and showed that the DAAO/Damino system could be appropriate to treat malignant brain tumors. Another approach is to impair or inhibit the molecules that prevent oxidative stress in tumor cells. This strategy was confirmed to work in many experimental solid tumors using ZnPP, a potent inhibitor of the ROSdefensive enzyme heme oxygenase [53] . Although oxidative stress based gene therapy is promising, it should be noted that high levels of oxidative stress are cytotoxic, resulting in decreased cell proliferation and increased apoptotic/necrotic cell death, whereas low or intermediate levels of oxidative stress are most effective in promoting cancer development [51] . Thereby, the level of oxidative stress should be optimized to achieve the better treatment and less side effects.
Therapeutic RNA鄄 Based Strategies
Abnormally high expression of some genes, such as Ras, cmyc, epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and cyclindependent kinase (CDK), may lead to tumor occurrence and development. In recent years, cancer therapy has involved approaches to silence or modulate the expression of the aforementioned genes. Several therapeutic strategies have been developed to manipulate the functions of these genes, and among them, RNA interference (RNAi) and antisense oligonucleotides (ASO) are the two most powerful approaches. Modified RNA molecules and ASOs are designed to bind target RNAs by wellcharacterized WatsonCrick base pairing and to modulate their function by suppressing protein expression or directly degrading mRNAs [54] . Herein, we will review the potential and challenges of these molecules in therapeutic applications.
RNAi鄄 based therapy
Small interfering RNAs (siRNAs) are small (2125 nt) dsRNAs that are mainly involved in guiding mRNA degradation. RNAibased gene therapy encompasses two approaches: plasmid or viral vectormediated delivery of short hairpin RNA (shRNA) precursors [55] and direct delivery of small dsRNAs (siRNAs or siRNA precursors) to target cells. The latter is more suitable for cancer therapy and can be applied for clinical purposes. RNAibased gene therapy has been used to treat wet agerelated macular degeneration and respiratory syncytial virus infection. Meanwhile, the application of RNAibased gene therapy for cancer is in the preclinical stage. Although RNAibased therapy has been confirmed efficacious, improvements are required and a number of challenges must be addressed to realize its full potential [5658] .
ASO鄄 based therapy
ASOs are singlestranded DNA and RNA molecules (1325 nt) that are precisely complementary to a particular mRNA. ASObased therapy has been extensively investigated over the past two decades owing to its conceptual simplicity, ease of design, and low cost [59, 60] . Recent studies showed that cancer cells treated with specific ASOs showed a marked decrease in tumorigenic p73 transcript and protein. However, this approach did not destroy the wildtype p73. ASOs rescued cells from apoptosis inhibition and decreased tumor cell proliferation [59] . Although remarkable progress has been made in ASObased therapy, there are several drawbacks to this type of gene therapy. First, ASOs can induce immune response in a sequencedependent or independent manner [61] . Many efforts have been made to avoid the activation of innate cellular immunity for safe application of RNAi in a clinical setting. For example, chemical modifications can be made to RNAs so not to induce type I IFN production [57] . Second, offtarget effects (OTEs) are known to arise from both sequencedependent and independent processes [55, 62] . Dykxhoorn . [51] demonstrated that an RNAcontaining sequence similar to mRNA 3爷untranslated regions (UTRs) might be prone to cause OTEs. However, such OTEs do not occur if the sequence is complementary to the open reading frame of mRNA transcripts [63, 64] . Therefore, detrimental OTEs can be reduced by ensuring that the siRNA sequence does not match the sequence of an mRNA爷s 3'UTRs. Chemical modification is also a promising approach to reduce potential OTEs [55] . Thus far, sequencemediated OTEs have not been reported in preclinical or early clinical trials of siRNAs [57] .
Immune Cell-Based Gene Therapy
Immunebased gene therapy can be used to treat tumors by enhancing antitumor immune response. Advances in immunology have led to the development of many novel immune therapies involving genemodified dendritic cells (DCs), genemodified T cells, and others.
DC鄄 based cancer gene therapy
DCs can be pulsed with tumorassociated antigen through viral vectors, nonviral vectors, cDNA, or mRNA. Therefore, modified DCs can present specific tumorassociated antigens [65] . Kyte . [66] transfected DCs with allogenic mRNA from whole tumors, and administered the DCs to 19 prostate cancer patients who had completed vaccination. Tcell vaccine responses were observed in 12 patients, and stable or decreased prostatespecific antigen levels were observed in 11 patients [66] . Furthermore, DCs can be engineered to express costimulatory molecules and adhesion molecules or to downregulate negative modulators, thereby increasing their T cellactivating ability. The costimulatory molecules include CD40 ligand (CD40L, CD154), CD70, OX40 ligand, and the adhesion molecule CD54, while the negative regulators include SOCS1. Schmitz .
[67] transferred the gene encoding CD40L into pancreatic tumor cellD C hybrids and observed that the efficiency of antitumoral response was elevated in an mouse model . Furthermore, DCs have been engineered to express other molecules, including cytokines, chemokines, and homing molecules [68, 69] . Some trials showed encouraging results such as good immune responses and safety of the use of DCs; however, the clinical efficacy of this method was limited.
T cell-based cancer gene therapy Because endogenous T cells lack an effective repertoire against tumor antigens, they can be modified to express tumorspecific Tcell receptor (TCR) genes. Some groups have engineered T cells to express natural 琢 茁 TCR. These modified T cells can recognize tumorspecific antigens in addition to the functions of endogenous TCRs [70] . Johnson .
[71] modified T cells using gp100specific TCR/TCR, and the genemodified T cells were detected for at least 1 month after treatment in patients with metastatic melanoma. In another approach, T cells can be transduced to express chimeric tumor antigenspecific receptors that contain a signalchain antibody. These chimeric receptors, called T bodies, target surface antigens in an MHCindependent manner [72] . Haynes . [73] studied the effect of T cells expressing scFvz chimeric receptors on the growth of human colon carcinoma in a severe combined immunodeficiency (SCID)/SCID mouse model or the growth of colon adenocarcinoma in syngeneic C57BL/6 mouse model. An efficient retroviral gene delivery system was used in their study and high and equivalent expression of scFvz and scFvg receptors was achieved in T cells [73] . Moreover, CCR7 was transferred into T cells to alter their homing [74] ; cytokineencoding genes, including IL4, IL10, and IL12, were transferred into T cells to enhance antitumor immunity [46] ; and a chimeric GMCSF IL12 receptor was transferred into T cells to increase their circulating halflife [75] . The data from preclinical and clinical trials suggest the feasibility of T cellbased cancer gene therapy , but there are still many challenges [76] . Similar to other strategies, T cellbased cancer gene therapy exhibits limited clinical efficacy although immune responses were obtained during clinical trials. Furthermore, some studies suggest that preferable antigen receptors must be carefully selected to avoid the development of lethal autoimmune responses [77] . However, the true potential of these strategies will remain uncertain until the results of the previously mentioned and new clinical trials are reported.
Conclusion
Although a wide variety of tu mor gene therapies have been investigated, the clinical applications of these strategies have not progressed sufficiently. Therefore, rigorous and innovative research efforts are required to exploit the full potential of gene therapy . Owing to its principles and advantages , gene therapy is expected to be a routine clinical practice in the coming years .
